English
简体中文
Total: £ 56.28
Published Date: 2025-10-16 | Pages: 119 | Tables: 119 | Pharma & Healthcare
The global Complement C5 Recombinant Monoclonal Antibody market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Complement C5 recombinant monoclonal antibody is a biologic drug designed to specifically target and block complement protein C5, which is a critical component of the immune system’s complement pathway.This class of drugs is used to treat diseases caused by excessive complement activation, such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica spectrum disorder (NMOSD).
From a downstream perspective, PNH accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Complement C5 Recombinant Monoclonal Antibody leading manufacturers including Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Amgen, Samsung Bioepis, Roche, etc., dominate supply; the top five capture approximately % of global revenue, with Regeneron Pharmaceuticals leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Complement C5 Recombinant Monoclonal Antibody market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Alexion Pharmaceuticals
Amgen
Samsung Bioepis
Roche
Segment by Type
Crovalimab
Ravulizumab
Eculizumab
Pozelimab
Others
Segment by Application
PNH
aHUS
CD55 Deficiency
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Complement C5 Recombinant Monoclonal Antibody study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Complement C5 Recombinant Monoclonal Antibody: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Complement C5 Recombinant Monoclonal Antibody Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Crovalimab
1.2.3 Ravulizumab
1.2.4 Eculizumab
1.2.5 Pozelimab
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Complement C5 Recombinant Monoclonal Antibody Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 PNH
1.3.3 aHUS
1.3.4 CD55 Deficiency
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Complement C5 Recombinant Monoclonal Antibody Revenue Estimates and Forecasts 2020-2031
2.2 Global Complement C5 Recombinant Monoclonal Antibody Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Estimates and Forecasts 2020-2031
2.4 Global Complement C5 Recombinant Monoclonal Antibody Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Complement C5 Recombinant Monoclonal Antibody Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Complement C5 Recombinant Monoclonal Antibody Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Crovalimab Market Size by Manufacturers
3.5.2 Ravulizumab Market Size by Manufacturers
3.5.3 Eculizumab Market Size by Manufacturers
3.5.4 Pozelimab Market Size by Manufacturers
3.5.5 Others Market Size by Manufacturers
3.6 Global Complement C5 Recombinant Monoclonal Antibody Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Complement C5 Recombinant Monoclonal Antibody Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Complement C5 Recombinant Monoclonal Antibody Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Complement C5 Recombinant Monoclonal Antibody Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Complement C5 Recombinant Monoclonal Antibody Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Type (2020-2031)
6.4 North America Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Complement C5 Recombinant Monoclonal Antibody Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Type (2020-2031)
7.4 Europe Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Complement C5 Recombinant Monoclonal Antibody Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Type (2020-2031)
9.4 Central and South America Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Complement C5 Recombinant Monoclonal Antibody Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Corporation Information
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Product Models, Descriptions and Specifications
11.1.4 Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales by Product in 2024
11.1.6 Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales by Application in 2024
11.1.7 Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales by Geographic Area in 2024
11.1.8 Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
11.1.9 Regeneron Pharmaceuticals Recent Developments
11.2 Alexion Pharmaceuticals
11.2.1 Alexion Pharmaceuticals Corporation Information
11.2.2 Alexion Pharmaceuticals Business Overview
11.2.3 Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Product Models, Descriptions and Specifications
11.2.4 Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales by Product in 2024
11.2.6 Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales by Application in 2024
11.2.7 Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales by Geographic Area in 2024
11.2.8 Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
11.2.9 Alexion Pharmaceuticals Recent Developments
11.3 Amgen
11.3.1 Amgen Corporation Information
11.3.2 Amgen Business Overview
11.3.3 Amgen Complement C5 Recombinant Monoclonal Antibody Product Models, Descriptions and Specifications
11.3.4 Amgen Complement C5 Recombinant Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Amgen Complement C5 Recombinant Monoclonal Antibody Sales by Product in 2024
11.3.6 Amgen Complement C5 Recombinant Monoclonal Antibody Sales by Application in 2024
11.3.7 Amgen Complement C5 Recombinant Monoclonal Antibody Sales by Geographic Area in 2024
11.3.8 Amgen Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
11.3.9 Amgen Recent Developments
11.4 Samsung Bioepis
11.4.1 Samsung Bioepis Corporation Information
11.4.2 Samsung Bioepis Business Overview
11.4.3 Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Product Models, Descriptions and Specifications
11.4.4 Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Sales by Product in 2024
11.4.6 Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Sales by Application in 2024
11.4.7 Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Sales by Geographic Area in 2024
11.4.8 Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
11.4.9 Samsung Bioepis Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Complement C5 Recombinant Monoclonal Antibody Product Models, Descriptions and Specifications
11.5.4 Roche Complement C5 Recombinant Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Roche Complement C5 Recombinant Monoclonal Antibody Sales by Product in 2024
11.5.6 Roche Complement C5 Recombinant Monoclonal Antibody Sales by Application in 2024
11.5.7 Roche Complement C5 Recombinant Monoclonal Antibody Sales by Geographic Area in 2024
11.5.8 Roche Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
11.5.9 Roche Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Complement C5 Recombinant Monoclonal Antibody Industry Chain
12.2 Complement C5 Recombinant Monoclonal Antibody Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Complement C5 Recombinant Monoclonal Antibody Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Complement C5 Recombinant Monoclonal Antibody Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Complement C5 Recombinant Monoclonal Antibody Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Complement C5 Recombinant Monoclonal Antibody Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Complement C5 Recombinant Monoclonal Antibody Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Complement C5 Recombinant Monoclonal Antibody Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Complement C5 Recombinant Monoclonal Antibody Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Complement C5 Recombinant Monoclonal Antibody Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Complement C5 Recombinant Monoclonal Antibody Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Complement C5 Recombinant Monoclonal Antibody Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Complement C5 Recombinant Monoclonal Antibody Sales by Region (2020-2025) & (K Units)
Table 8. Global Complement C5 Recombinant Monoclonal Antibody Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Complement C5 Recombinant Monoclonal Antibody Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Complement C5 Recombinant Monoclonal Antibody Sales Share by Manufacturers (2020-2025)
Table 12. Global Complement C5 Recombinant Monoclonal Antibody Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Complement C5 Recombinant Monoclonal Antibody Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Complement C5 Recombinant Monoclonal Antibody by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Complement C5 Recombinant Monoclonal Antibody as of 2024)
Table 16. Global Complement C5 Recombinant Monoclonal Antibody Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Complement C5 Recombinant Monoclonal Antibody Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Complement C5 Recombinant Monoclonal Antibody Manufacturing Base and Headquarters
Table 19. Global Complement C5 Recombinant Monoclonal Antibody Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Complement C5 Recombinant Monoclonal Antibody Sales by Type (2020-2025) & (K Units)
Table 23. Global Complement C5 Recombinant Monoclonal Antibody Sales by Type (2026-2031) & (K Units)
Table 24. Global Complement C5 Recombinant Monoclonal Antibody Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Complement C5 Recombinant Monoclonal Antibody Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Complement C5 Recombinant Monoclonal Antibody ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Complement C5 Recombinant Monoclonal Antibody Sales by Application (2020-2025) & (K Units)
Table 29. Global Complement C5 Recombinant Monoclonal Antibody Sales by Application (2026-2031) & (K Units)
Table 30. Complement C5 Recombinant Monoclonal Antibody High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Complement C5 Recombinant Monoclonal Antibody Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Complement C5 Recombinant Monoclonal Antibody Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Complement C5 Recombinant Monoclonal Antibody ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Complement C5 Recombinant Monoclonal Antibody Growth Accelerators and Market Barriers
Table 37. North America Complement C5 Recombinant Monoclonal Antibody Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Complement C5 Recombinant Monoclonal Antibody Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Complement C5 Recombinant Monoclonal Antibody Growth Accelerators and Market Barriers
Table 40. Europe Complement C5 Recombinant Monoclonal Antibody Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Complement C5 Recombinant Monoclonal Antibody Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Growth Accelerators and Market Barriers
Table 45. Southeast Asia Complement C5 Recombinant Monoclonal Antibody Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Complement C5 Recombinant Monoclonal Antibody Investment Opportunities and Key Challenges
Table 47. Central and South America Complement C5 Recombinant Monoclonal Antibody Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Regeneron Pharmaceuticals Corporation Information
Table 51. Regeneron Pharmaceuticals Description and Major Businesses
Table 52. Regeneron Pharmaceuticals Product Models, Descriptions and Specifications
Table 53. Regeneron Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Regeneron Pharmaceuticals Sales Value Proportion by Product in 2024
Table 55. Regeneron Pharmaceuticals Sales Value Proportion by Application in 2024
Table 56. Regeneron Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 57. Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
Table 58. Regeneron Pharmaceuticals Recent Developments
Table 59. Alexion Pharmaceuticals Corporation Information
Table 60. Alexion Pharmaceuticals Description and Major Businesses
Table 61. Alexion Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Alexion Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Alexion Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Alexion Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Alexion Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
Table 67. Alexion Pharmaceuticals Recent Developments
Table 68. Amgen Corporation Information
Table 69. Amgen Description and Major Businesses
Table 70. Amgen Product Models, Descriptions and Specifications
Table 71. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Amgen Sales Value Proportion by Product in 2024
Table 73. Amgen Sales Value Proportion by Application in 2024
Table 74. Amgen Sales Value Proportion by Geographic Area in 2024
Table 75. Amgen Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
Table 76. Amgen Recent Developments
Table 77. Samsung Bioepis Corporation Information
Table 78. Samsung Bioepis Description and Major Businesses
Table 79. Samsung Bioepis Product Models, Descriptions and Specifications
Table 80. Samsung Bioepis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Samsung Bioepis Sales Value Proportion by Product in 2024
Table 82. Samsung Bioepis Sales Value Proportion by Application in 2024
Table 83. Samsung Bioepis Sales Value Proportion by Geographic Area in 2024
Table 84. Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
Table 85. Samsung Bioepis Recent Developments
Table 86. Roche Corporation Information
Table 87. Roche Description and Major Businesses
Table 88. Roche Product Models, Descriptions and Specifications
Table 89. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Roche Sales Value Proportion by Product in 2024
Table 91. Roche Sales Value Proportion by Application in 2024
Table 92. Roche Sales Value Proportion by Geographic Area in 2024
Table 93. Roche Complement C5 Recombinant Monoclonal Antibody SWOT Analysis
Table 94. Roche Recent Developments
Table 95. Key Raw Materials Distribution
Table 96. Raw Materials Key Suppliers
Table 97. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 98. Milestones in Production Technology Evolution
Table 99. Distributors List
Table 100. Market Trends and Market Evolution
Table 101. Market Drivers and Opportunities
Table 102. Market Challenges, Risks, and Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Complement C5 Recombinant Monoclonal Antibody Product Picture
Figure 2. Global Complement C5 Recombinant Monoclonal Antibody Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Crovalimab Product Picture
Figure 4. Ravulizumab Product Picture
Figure 5. Eculizumab Product Picture
Figure 6. Pozelimab Product Picture
Figure 7. Others Product Picture
Figure 8. Global Complement C5 Recombinant Monoclonal Antibody Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. PNH
Figure 10. aHUS
Figure 11. CD55 Deficiency
Figure 12. Others
Figure 13. Complement C5 Recombinant Monoclonal Antibody Report Years Considered
Figure 14. Global Complement C5 Recombinant Monoclonal Antibody Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 16. Global Complement C5 Recombinant Monoclonal Antibody Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Complement C5 Recombinant Monoclonal Antibody Revenue Market Share by Region (2020-2031)
Figure 18. Global Complement C5 Recombinant Monoclonal Antibody Sales (2020-2031) & (K Units)
Figure 19. Global Complement C5 Recombinant Monoclonal Antibody Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Complement C5 Recombinant Monoclonal Antibody Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Complement C5 Recombinant Monoclonal Antibody Sales Volume Market Share in 2024
Figure 22. Global Complement C5 Recombinant Monoclonal Antibody Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Crovalimab Revenue Market Share by Manufacturer in 2024
Figure 25. Ravulizumab Revenue Market Share by Manufacturer in 2024
Figure 26. Eculizumab Revenue Market Share by Manufacturer in 2024
Figure 27. Pozelimab Revenue Market Share by Manufacturer in 2024
Figure 28. Others Revenue Market Share by Manufacturer in 2024
Figure 29. Global Complement C5 Recombinant Monoclonal Antibody Sales Market Share by Type (2020-2031)
Figure 30. Global Complement C5 Recombinant Monoclonal Antibody Revenue Market Share by Type (2020-2031)
Figure 31. Global Complement C5 Recombinant Monoclonal Antibody Sales Market Share by Application (2020-2031)
Figure 32. Global Complement C5 Recombinant Monoclonal Antibody Revenue Market Share by Application (2020-2031)
Figure 33. North America Complement C5 Recombinant Monoclonal Antibody Sales YoY (2020-2031) & (K Units)
Figure 34. North America Complement C5 Recombinant Monoclonal Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 35. North America Top 5 Manufacturers Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) in 2024
Figure 36. North America Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Type (2020- 2031)
Figure 37. North America Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 38. North America Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Application (2020-2031)
Figure 39. North America Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Application (2020-2031)
Figure 40. US Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 41. Canada Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 42. Mexico Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 43. Europe Complement C5 Recombinant Monoclonal Antibody Sales YoY (2020-2031) & (K Units)
Figure 44. Europe Complement C5 Recombinant Monoclonal Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 45. Europe Top 5 Manufacturers Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) in 2024
Figure 46. Europe Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Type (2020-2031)
Figure 47. Europe Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Type (2020-2031)
Figure 48. Europe Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Application (2020-2031)
Figure 49. Europe Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Application (2020-2031)
Figure 50. Germany Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 51. France Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 52. U.K. Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 53. Italy Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 54. Russia Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 55. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales YoY (2020-2031) & (K Units)
Figure 56. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Asia-Pacific Top 8 Manufacturers Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) in 2024
Figure 58. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Type (2020- 2031)
Figure 59. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 60. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Application (2020-2031)
Figure 61. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Application (2020-2031)
Figure 62. Indonesia Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 63. Japan Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 64. South Korea Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 65. China Taiwan Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 66. India Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2031) & (US$ Million)
Figure 67. Central and South America Complement C5 Recombinant Monoclonal Antibody Sales YoY (2020-2031) & (K Units)
Figure 68. Central and South America Complement C5 Recombinant Monoclonal Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 69. Central and South America Top 5 Manufacturers Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) in 2024
Figure 70. Central and South America Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Type (2021-2031)
Figure 71. Central and South America Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Type (2020-2031)
Figure 72. Central and South America Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Application (2020-2031)
Figure 73. Central and South America Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Application (2020-2031)
Figure 74. Brazil Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2025) & (US$ Million)
Figure 75. Argentina Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2025) & (US$ Million)
Figure 76. Middle East, and Africa Complement C5 Recombinant Monoclonal Antibody Sales YoY (2020-2031) & (K Units)
Figure 77. Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 78. Middle East and Africa Top 5 Manufacturers Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) in 2024
Figure 79. Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Type (2021-2031)
Figure 80. South America Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Type (2020-2031)
Figure 81. Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Sales Volume (K Units) by Application (2020-2031)
Figure 82. Middle East and Africa Complement C5 Recombinant Monoclonal Antibody Sales Revenue (US$ Million) by Application (2020-2031)
Figure 83. GCC Countries Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2025) & (US$ Million)
Figure 84. Turkey Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2025) & (US$ Million)
Figure 85. Egypt Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2025) & (US$ Million)
Figure 86. South Africa Complement C5 Recombinant Monoclonal Antibody Revenue (2020-2025) & (US$ Million)
Figure 87. Complement C5 Recombinant Monoclonal Antibody Industry Chain Mapping
Figure 88. Regional Complement C5 Recombinant Monoclonal Antibody Manufacturing Base Distribution (%)
Figure 89. Global Complement C5 Recombinant Monoclonal Antibody Production Market Share by Region (2020-2031)
Figure 90. Complement C5 Recombinant Monoclonal Antibody Production Process
Figure 91. Regional Complement C5 Recombinant Monoclonal Antibody Production Cost Structure
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed
